Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 1;21(1):26-36.
doi: 10.1093/neuonc/noy137.

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group

Raymond Y Huang  1 , Wenya Linda Bi  2 , Michael Weller  3 , Thomas Kaley  4 , Jaishri Blakeley  5 , Ian Dunn  2 , Evanthia Galanis  6 , Matthias Preusser  7 , Michael McDermott  8 , Leland Rogers  9 , Jeffrey Raizer  10 , David Schiff  11 , Riccardo Soffietti  12 , Jörg-Christian Tonn  13 , Michael Vogelbaum  14 , Damien Weber  15 , David A Reardon  16 , Patrick Y Wen  16
Affiliations
Review

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group

Raymond Y Huang et al. Neuro Oncol. .

Abstract

No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.

PubMed Disclaimer

References

    1. Ostrom QT, Gittleman H, Liao P, et al. . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 4):iv1–63. - PMC - PubMed
    1. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006;5(12):1045–1054. - PubMed
    1. Backer-Grøndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol. 2012;5(3):231–242. - PMC - PubMed
    1. Olar A, Wani KM, Sulman EP, et al. . Mitotic index is an independent predictor of recurrence-free survival in meningioma. Brain Pathol. 2015;25(3):266–275. - PMC - PubMed
    1. Pearson BE, Markert JM, Fisher WS, et al. . Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus. 2008;24(5):E3. - PubMed

Publication types

MeSH terms